FIGURE 2
FROM:
HSV Oncolytic Therapy Upregulates Interferon-Inducible Chemokines and Recruits Immune Effector Cells in Ovarian Cancer
Fabian Benencia, Maria C. Courrèges, José R. Conejo-García, Alisha Mohamed-Hadley, Lin Zhang, Ronald J. Buckanovich, Richard Carroll, Nigel Fraser and George Coukos
BACK TO ARTICLEFigure 2.
ELISA of (A, C) IP-10 and (B, D) MIG in supernatants of monocyte (A, B) or DC (C, D) cultures 72 h after HSV-1716 infection (1 m.o.i.). Immediately after infection, 104 U/ml anti-mouse IFN-
or IFN-
or both was added to cell cultures where indicated. Control cultures were infected with UV-inactivated HSV-1716 (mock). (A) HSV-1716 vs mock, P < 0.001; HSV-1716 vs anti-IFN-, P < 0.01; HSV-1716 vs anti-IFN-, P < 0.001; HSV-1716 vs anti-IFN-/, P < 0.001. (B) HSV-1716 vs mock, P < 0.001; HSV-1716 vs anti-IFN-, P < 0.001; HSV-1716 vs anti-IFN-, P < 0.001; HSV-1716 vs anti-IFN-/, P < 0.001. (C) HSV-1716 vs mock, P < 0.001; HSV-1716 vs anti-IFN-, P < 0.05; HSV-1716 vs anti-IFN-, P < 0.001; HSV-1716 vs anti-IFN-/, P < 0.001. (D) HSV-1716 vs mock, P < 0.001; HSV-1716 vs anti-IFN-, ns; HSV-1716 vs anti-IFN-, ns; HSV-1716 vs anti-IFN-/, ns. ANOVA, Tukey–Kramer multicomparison posttest.
